Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation
about
Oritavancin for acute bacterial skin and skin structure infections.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsOritavancin--an investigational glycopeptide antibiotic.Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts).Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Emergence and management of drug-resistant enterococcal infections.Vancomycin resistance: are there better glycopeptides coming?Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.Intracytoplasmic trapping of influenza virus by a lipophilic derivative of aglycoristocetin.Macrophage killing of bacterial and fungal pathogens is not inhibited by intense intracellular accumulation of the lipoglycopeptide antibiotic oritavancin.
P2860
Q36086423-DB592298-4000-4F03-902A-9D834E5878F7Q36393640-C2783419-E2D4-4DA0-91E6-6843579907E8Q36426011-9F9E60BA-1CAC-47D1-8B74-F795446E1370Q36660619-B708F446-8D1A-4920-B04E-5E2841A8A018Q37071199-E79B291D-2E2E-4C8C-ABD3-66B934E3A1C9Q37174100-40AFC5A8-E7FC-4E91-B80B-EA766E5150F6Q37291346-28B7F4A8-DFC3-4C4A-A8AB-C5A250E2BC87Q37340562-E8A684D7-B690-4AD5-A988-37264DBA7EDFQ38233471-6E1BA478-EDCC-4637-A85D-219C92CAFAB9Q38646905-7B29CC9D-C3F6-44C3-B07C-1F662453C6E1Q39031976-77A16181-69FC-4FC0-ABFD-69D380A883F3Q39323887-1B23E8FB-9B04-4502-AECC-7B4586938D37Q39373932-56AB8FB1-173A-4083-B531-719190FE8220
P2860
Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@ast
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@en
type
label
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@ast
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@en
prefLabel
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@ast
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@en
P2860
P1476
Mixed-lipid storage disorder i ...... eptional cellular accumulation
@en
P2093
Jennifer Saffran
Marie-Paule Mingeot-Leclercq
P2860
P304
P356
10.1128/AAC.49.5.1695-1700.2005
P407
P577
2005-05-01T00:00:00Z